WuXi Biologics IPO reaps $509M windfall; Intellia strikes CRISPR pact with San Raffaele
→ WuXi Biologics raised HK$3.8 billion ($509 million) as it had set its sights on last month, offering 193 million shares at HK$20.60 ($2.64). The Wuxi, China-based company will list on the Hong Kong Exchange. BofA Merrill Lynch, Morgan Stanley and China Merchants Securities are the joint bookrunners on the deal which is expected to price June 6, 2017.
→ Cambridge, Mass-based Intellia has partnered with San Raffaele University in Italy. The two entered a three-year agreement to collaborate on research using Intellia’s CRISPR/Cas9 genome editing techniques to engineer new T Cell therapies to fight cancer. Intellia has been optimizing its gene editing system in preclinical trials in hopes of developing the accuracy to create a one-time cure for diseases. This is the first external partnership of the eXtellia division.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.